HCW Biologics Surges to 229th Most Traded Stock with 91794.87% Volume Spike

On May 13, 2025, HCW Biologics (HCWB) experienced a significant surge in trading volume, with a total turnover of 495 million, marking a 91794.87% increase from the previous day. This substantial rise in trading volume positioned HCW Biologics as the 229th most traded stock of the day, reflecting a notable increase in investor interest and market activity. The stock price of HCW Biologics soared by 92.90%.

HCW Biologics recently announced positive results from studies on its proprietary fusion protein, HCW9206. This breakthrough has garnered significant attention, as HCW9206 represents a novel class of immunotherapeutic that can deliver synergistic signals from three different immune-stimulatory cytokines. The company highlighted that the activity of HCW9206 was significantly superior compared to standard methods employing anti-CD3/anti-CD28 and IL-2 reagents for CAR lentiviral transduction and subsequent expansion and persistence of human CAR-Ts.

CAR-Ts, or chimeric antigen receptor T cells, are a revolutionary technology with several CD19-specific CAR-T therapies already approved by the FDA for the treatment of B-cell malignancies. This technology continues to play an increasingly pivotal and expanding role in the treatment of cancer and has significant potential to treat autoimmune diseases and age-related diseases. The positive results from the studies on HCW9206 have further solidified HCW Biologics' position as a leader in the biopharmaceutical industry, driving investor confidence and market enthusiasm.